|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN110241086A
(zh)
*
|
2012-06-11 |
2019-09-17 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
IN2015KN00329A
(enExample)
|
2012-08-09 |
2015-07-10 |
Univ Leland Stanford Junior |
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201507026WA
(en)
*
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2014172584A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Baylor College Of Medicine |
IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
|
|
CN105431456A
(zh)
*
|
2013-06-14 |
2016-03-23 |
休斯敦系统大学 |
用修饰的嵌合抗原受体靶向肿瘤新生血管
|
|
EP3021853A1
(en)
*
|
2013-07-18 |
2016-05-25 |
Baylor College Of Medicine |
Method of enhancing potency of immune cells
|
|
JP6936934B2
(ja)
|
2013-09-24 |
2021-09-22 |
メディシナ セラピューティクス インコーポレイテッド |
インターロイキン−４受容体結合融合タンパク質及びその使用
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
RU2751362C2
(ru)
|
2014-12-29 |
2021-07-13 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
AU2015380397B2
(en)
|
2015-01-31 |
2021-10-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
SG11201707182WA
(en)
|
2015-03-05 |
2017-10-30 |
Hutchinson Fred Cancer Res |
Immunomodulatory fusion proteins and uses thereof
|
|
CA2980039A1
(en)
*
|
2015-03-20 |
2016-09-29 |
Children's National Medical Center |
Generating virus or other antigen-specific t cells from a naive t cell population
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
JP6803339B2
(ja)
|
2015-04-21 |
2020-12-23 |
エンリヴェックス セラピューティクス リミテッド |
治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN104910279B
(zh)
*
|
2015-06-05 |
2019-02-22 |
重庆精准生物技术有限公司 |
靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
WO2018161064A1
(en)
*
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
CN108884460B
(zh)
*
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN118546961A
(zh)
*
|
2016-08-26 |
2024-08-27 |
贝勒医学院 |
用于细胞治疗的组成型活性细胞因子受体
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
CN109983027A
(zh)
|
2016-10-20 |
2019-07-05 |
细胞基因公司 |
基于cereblon的可异二聚化嵌合抗原受体
|
|
US11654158B2
(en)
|
2016-11-17 |
2023-05-23 |
2Seventy Bio, Inc. |
TGFBeta signal convertor
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
GB201702617D0
(en)
*
|
2017-02-17 |
2017-04-05 |
Autolus Ltd |
Receptor
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
KR20190141695A
(ko)
|
2017-04-13 |
2019-12-24 |
센티 바이오사이언시스, 인코포레이티드 |
병용 암 면역요법
|
|
CA3078434A1
(en)
|
2017-10-10 |
2019-04-18 |
Medicenna Therapeutics, Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CN109880803B
(zh)
*
|
2017-12-06 |
2024-06-07 |
恺兴生命科技(上海)有限公司 |
嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
AU2019227979B2
(en)
*
|
2018-03-02 |
2024-09-05 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
|
WO2019239213A2
(en)
|
2018-06-01 |
2019-12-19 |
Medicenna Therapeutics Inc. |
Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
|
|
WO2019232523A1
(en)
*
|
2018-06-01 |
2019-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
CN110615843B
(zh)
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
SI3844267T1
(sl)
|
2018-08-31 |
2025-10-30 |
Novartis Ag |
Postopki izdelave celic, ki izražajo receptorje himernega antigena
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
CA3116138A1
(en)
|
2018-10-17 |
2020-04-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US20200147137A1
(en)
*
|
2018-11-08 |
2020-05-14 |
WUGEN, Inc. |
Compositions and methods for treatment of cancer
|
|
CN109735558B
(zh)
*
|
2018-12-12 |
2022-04-15 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
IL285941B1
(en)
|
2019-03-01 |
2026-08-01 |
Allogene Therapeutics Inc |
Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
|
|
IL328846A
(en)
*
|
2019-03-01 |
2026-08-01 |
Allogene Therapeutics Inc |
Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
|
|
MA55911A
(fr)
|
2019-05-08 |
2022-03-16 |
2Seventy Bio Inc |
Lymphocytes t génétiquement modifiés
|
|
KR20220101073A
(ko)
|
2019-08-30 |
2022-07-19 |
예일 유니버시티 |
핵산을 세포로 전달하기 위한 조성물 및 방법
|
|
BR112022003553A2
(pt)
|
2019-08-30 |
2022-05-24 |
Allogene Therapeutics Inc |
Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
|
|
KR102275668B1
(ko)
*
|
2019-09-26 |
2021-07-12 |
충북대학교 산학협력단 |
면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
PE20221757A1
(es)
|
2020-02-24 |
2022-11-11 |
Allogene Therapeutics Inc |
Celulas t con car de bcma con actividades mejoradas
|
|
US20230138428A1
(en)
|
2020-02-25 |
2023-05-04 |
Quell Therapeutics Limited |
Chimeric receptors for use in engineered cells
|
|
WO2022047424A1
(en)
|
2020-08-31 |
2022-03-03 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
US12702710B2
(en)
|
2020-10-12 |
2026-08-11 |
Medicenna Therapeutics Inc. |
Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
|
|
CA3231615A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Mikko SIURALA |
Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
|
|
AU2023248532A1
(en)
|
2022-04-08 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Multipartite receptor and signaling complexes
|
|
CN120641131A
(zh)
|
2022-12-01 |
2025-09-12 |
耶鲁大学 |
用于细胞内有效载荷递送的刺激反应性无痕工程化平台
|
|
WO2024140501A1
(zh)
*
|
2022-12-27 |
2024-07-04 |
广州瑞风生物科技有限公司 |
一种融合蛋白及其应用
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
JP2026507781A
(ja)
|
2023-01-23 |
2026-03-06 |
メディツィニシェ ホゥーシュル ハノーファー |
キメラ抗原受容体
|
|
CN120787258A
(zh)
|
2023-02-07 |
2025-10-14 |
圭尔医疗有限公司 |
Treg细胞培养方法
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN116284449B
(zh)
*
|
2023-02-27 |
2024-11-19 |
深圳市先康达生命科学有限公司 |
增强型TGF-βR嵌合受体及其应用
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
EP4680748A1
(en)
|
2023-03-13 |
2026-01-21 |
Arsenal Biosciences, Inc. |
Synthetic pathway activators
|
|
WO2024194605A1
(en)
|
2023-03-17 |
2024-09-26 |
Quell Therapeutics Limited |
Treg therapy
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024194355A1
(en)
|
2023-03-20 |
2024-09-26 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024193687A1
(en)
*
|
2023-03-23 |
2024-09-26 |
Nanjing Legend Biotech Co., Ltd. |
Inverted cytokine receptors and methods of use thereof
|
|
WO2024211900A1
(en)
*
|
2023-04-06 |
2024-10-10 |
Memorial Sloan-Kettering Cancer Center |
Il-10 receptor antibodies and methods of use thereof
|
|
CN116496417B
(zh)
*
|
2023-06-27 |
2023-10-10 |
北京市肿瘤防治研究所 |
含有膜型il7的融合蛋白及t细胞
|
|
EP4747272A1
(en)
*
|
2023-07-17 |
2026-05-27 |
Legend Biotech USA Inc. |
Fusion proteins and methods of use thereof
|
|
US20260176598A1
(en)
|
2024-07-04 |
2026-06-25 |
Quell Therapeutics Limited |
Expression construct
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|